Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial
- 1 November 2010
- journal article
- research article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 15 (8), 1115-1124
- https://doi.org/10.3851/imp1695
Abstract
Background: No data on once-daily dosing of nucleoside analogues in African children currently exist. We compared the pharmacokinetics (PK) of once- versus twice-daily lamivudine and abacavir treatment using the World Health Organization recommended weight band dosing of scored adult tablets. Methods: HIV type-1 (HIV-1)-infected Ugandan children aged 3–12 years receiving antiretroviral therapy that included lamivudine and abacavir twice daily (total 150+300 mg, 225+450 mg and 225/300+600 mg daily for 12–0–24) and maximum concentrations (Cmax) were compared by geometric mean ratios (GMRs). Results: A total of 41 HIV-1-infected children (median age of 7 years) and n=23, n=14 and n=4 in 12–0–24 was 13.0 and 12.0 mg•h/l for once- and twice-daily lamivudine (GMR 1.09, 90% confidence intervals [CI] 0.98–1.20) and 15.3 and 15.6 mg•h/l for once- and twice-daily abacavir (GMR 0.98, 90% CI 0.89–1.08), respectively, with no difference in 3–6 versus 7–12 year olds. Cmax was 76% (lamivudine) and 64% (abacavir) higher on once-daily regimens. For both children and caregivers, once-daily dosing of lamivudine plus abacavir was highly acceptable and strongly preferred over twice-daily. Conclusions: In children aged 3–12 years, AUC0–24 of lamivudine and abacavir were bioequivalent on once-and twice-daily regimens. Once-daily dosing of abacavir and lamivudine could provide an alternative dosing strategy for HIV-1-infected children, with high acceptability and strong preference suggesting the potential for improved adherence.Keywords
This publication has 24 references indexed in Scilit:
- Steady-State Pharmacokinetics of Abacavir in Plasma and Intracellular Carbovir Triphosphate following Administration of Abacavir at 600 Milligrams Once Daily and 300 Milligrams Twice Daily in Human Immunodeficiency Virus-Infected SubjectsAntimicrobial Agents and Chemotherapy, 2009
- Longitudinal Antiretroviral Adherence in HIV+ Ugandan Parents and Their Children Initiating HAART in the MTCT-Plus Family Treatment Model: Role of Depression in Declining Adherence Over TimeAIDS and Behavior, 2009
- Abacavir Pharmacokinetics During Chronic Therapy in HIV-1-Infected Adolescents and Young AdultsClinical Pharmacology & Therapeutics, 2008
- Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapyHIV Medicine, 2008
- Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adultsJournal of Antimicrobial Chemotherapy, 2008
- Increasing Antiretroviral Drug Access for Children With HIV InfectionPublished by American Academy of Pediatrics (AAP) ,2007
- Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and FacilitatorsPLoS Medicine, 2006
- Adherence and Acceptability of Once Daily Lamivudine and Abacavir in Human Immunodeficiency Virus Type-1 Infected ChildrenThe Pediatric Infectious Disease Journal, 2006
- Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort studyBMJ, 2006
- Comparison of the Plasma Pharmacokinetics of Lamivudine During Twice and Once Daily Administration in Patients with HIVClinical Pharmacokinetics, 2001